CLINICAL DEVELOPMENT

 

People count on us to make medicines and vaccines that have well documented safety and effectiveness profiles and offer value. Clinical trials (also known as clinical studies) are a critical step in this process.

Each clinical trial is designed to answer certain research questions. They follow strict, predefined protocols to ensure safe and accurate results. Each phase has a different purpose in the development of a medicine or vaccine:

• Phase I:Researchers test an experimental drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine an appropriate dosage, trace what happens to the compound in the body, and begin to identify side effects.

• Phase II:The drug or treatment being studied is given to a larger group of people with the disease (100-300) to obtain preliminary evidence of an effect and to further evaluate its safety. If there is evidence of an effect and the risks are considered acceptable, the drug may move to the next stage.

• Phase III:This phase of trial tests a drug candidate in a larger number of people with the disease (1,000-3,000), further testing its effectiveness and monitoring for side effects. In some cases this will be compared to a treatment standard, if one is already available.

• Phase IV:After a drug or treatment has been approved by the appropriate government and regulatory agencies and is being marketed, we may study its safety and effectiveness over a longer period of time and in a larger number of people. We may also continue to study some of our marketed products for new indications. Thousands of people usually participate in Phase IV trials.

At MSD, our clinical trials are designed, conducted and monitored in adherence to the same standards, whether they take place in the United States or elsewhere around the world. In conducting clinical trials, we also adhere to the guidelines of The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

Interested in Participating in One of Our Clinical Trials?

MSD-sponsored clinical trials in patients are registered on ClinicalTrials.gov, a service of the U.S. National Institutes of Health. Information about ongoing clinical trials is also available online through the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

Currently recruiting

IFPMA Clinical Trials Portal

Note: MSDand Schering-Plough have combined our global operations under the name Merck & Co., Inc. We are working to update our entries in these two online registries to reflect this change. In the meantime, you can search for information about our ongoing clinical trials by using both "MSD" and "Schering-Plough" as search terms.

Results of MSD-sponsored Clinical Trials

We are committed to the timely registration of clinical trials in patients and disclosure of those clinical trial results regardless of their outcome. We seek to provide balanced and accurate information about our studies, and have strict guidelines in place to guide publication. We also disclose medically important safety data from other studies. In addition to publishing our clinical trial results in peer-reviewed medical journals, we post study results of our marketed products on ClinicalTrials.gov.

As part of MSD commitment and support to its valued customers, a new service has been launched that enhances our ongoing efforts to provide you with the medical information you need to use our products safely and effectively.

A specific inbox has been created with the following e-mail addresses: For Adverse Drug Reaction and Product Quality:

egypt.pharmacovigilance@merck.com

For Medical Inquiry:

dpoc.egypt@merck.com

You are therefore, kindly requested, to forward your inquiries to the abovementioned address for the efficient further processing of your inquiries.

We assure you of our prompt reply, Sincerely,

MSD Egypt Medical Team

In case of any adverse event please contact:
Dr Marian Mounir Drug Safety,
Pharmacovigilance Egypt
marianne.mounir@merck.com